Exact Mass: 347.18583920000003
Exact Mass Matches: 347.18583920000003
Found 500 metabolites which its exact mass value is equals to given mass value 347.18583920000003,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
4,4-Disubstituted cyclohexenone
Methyl 4-(2-benzylbenzoyl)-2,5-dimethyl-1H-pyrrole-3-carboxylate
C22H21NO3 (347.15213560000007)
D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents > D002120 - Calcium Channel Agonists D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
AS 1842856
C18H22FN3O3 (347.16451140000004)
Pyrafoline D
3,8-Dimethyl-3-(4-methylpent-3-en-1-yl)-3,11-dihydropyrano[3,2-a]carbazol-9-ol is a natural product found in Murraya euchrestifolia, Murraya koenigii, and Murraya kwangsiensis with data available. Pyrafoline D is found in herbs and spices. Pyrafoline D is an alkaloid from seeds of Murraya koenigii (curryleaf tree). Alkaloid from seeds of Murraya koenigii (curryleaf tree). Pyrafoline D is found in herbs and spices.
(R)-Mahanine
(R)-Mahanine is found in herbs and spices. (R)-Mahanine is an alkaloid from the leaves of Murraya koenigii (curry leaf tree). Alkaloid from the leaves of Murraya koenigii (curry leaf tree). (R)-Mahanine is found in herbs and spices.
Mukoenine B
Mukoenine B is found in herbs and spices. Mukoenine B is an alkaloid from Murraya koenigii (curryleaf tree). Alkaloid from Murraya koenigii (curryleaf tree). Mukoenine B is found in herbs and spices.
Murrayazolinol
Minor alkaloid from the stem bark of Murraya koenigii (curryleaf tree). Murrayazolinol is found in herbs and spices. Murrayazolinol is found in herbs and spices. Minor alkaloid from the stem bark of Murraya koenigii (curryleaf tree).
3,8-Dihydroxydecanoylcarnitine
3,8-Dihydroxydecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,8-Dihydroxydecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,8-Dihydroxydecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,8-Dihydroxydecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,6-Dihydroxydecanoylcarnitine
3,6-Dihydroxydecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,6-Dihydroxydecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,6-Dihydroxydecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,6-Dihydroxydecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,4-Dihydroxydecanoylcarnitine
3,4-Dihydroxydecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,4-Dihydroxydecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,4-Dihydroxydecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,4-Dihydroxydecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,9-Dihydroxydecanoylcarnitine
3,9-Dihydroxydecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,9-Dihydroxydecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,9-Dihydroxydecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,9-Dihydroxydecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,7-Dihydroxydecanoylcarnitine
3,7-Dihydroxydecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,7-Dihydroxydecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,7-Dihydroxydecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,7-Dihydroxydecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,5-Dihydroxydecanoylcarnitine
3,5-Dihydroxydecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,5-Dihydroxydecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,5-Dihydroxydecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,5-Dihydroxydecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Eliprodil
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents Eliprodil(SL-820715) is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM). IC50 value: Target: NR2B-NMDA antagonist Human N-type Ca2+ channel currents were inhibited by ifenprodil and eliprodil with IC50 values of 50 microM and 10 microM respectively whereas P-type Ca2+ channel currents were inhibited reversibly by ifenprodil and eliprodil with approximate IC50 values of 60 microM and 9 microM respectively. eliprodil (1 microm) produced a moderate reverse rate-dependent prolongation of the action potential duration (7.4+/-1.5, 8.9+/-2.1 and 9.9+/-1.8\% at cycle lengths of 300, 1000 and 5000 ms, respectively; n=9).
5-Amino-1-[(2R,3R,4S,5R)-5-[(benzylamino)methyl]-3,4-dihydroxyoxolan-2-yl]imidazole-4-carboxamide
C16H21N5O4 (347.15934660000005)
3-(4-((3-Phenoxybenzyl)amino)phenyl)propanoic acid
C22H21NO3 (347.15213560000007)
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities[1][2][3][4].
Baratol
C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Indoramin is an orally active antihypertensive agent. Indoramin is also selective for the α1A-adrenoceptor[1].
Methyl 3-benzoyloxy-8-(3-hydroxypropyl)-8-azabicyclo[3.2.1]octane-2-carboxylate
10,20-Dehydro[12,13-dehydroprolyl]-2-(1,1-dimethylallyltryptophyl)diketopiperazine
GW9508
C22H21NO3 (347.15213560000007)
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities[1][2][3][4].
INDORAMIN
C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Indoramin is an orally active antihypertensive agent. Indoramin is also selective for the α1A-adrenoceptor[1].
(+)-6-(6-Hydroxy-1-methyl-2,3,5,6,7,7a-hexahydro-1H-indol-7-yl)-2,3,4-trimethoxy-benzaldehyd|(+)-6-(6-hydroxy-1-methyl-2,3,5,6,7,7a-hexahydro-1H-indol-7-yl)-2,3,4-trimethoxy-benzaldehyde
delta-(L-alpha-aminoadipoyl)-L-serine-D-valine|delta-(L-alpha-aminoadipyl)-L-seryl-D-valine|L,L,D-alpha-aminodipoyl-serinyl-valine
4,6,8-trimethoxy-3-(2-methoxy-3-methyl-but-3-enyl)-1-methyl-1H-quinolin-2-one|Ptelefolin-methylether|Ptelefolinmethylether
4-methoxy-3-methyl-5-[(2Z,11aS)-3at,11t-epoxy-1c-methyl-(11ar,11bc)-dodecahydro-furo[3,2-c]pyrido[1,2-a]azepin-2-ylidene]-5H-furan-2-one|pyridostemin|stemocurtisine
Di-O-acetyllycofolin|Lycofolindiacetat
C20H29NO4 (347.20964740000005)
R-4-benzyl-3-((R)-3-hydroxy-2,2-dimethyloctanoyl)oxazolidin-2-one
C20H29NO4 (347.20964740000005)
mahanine
Mahanine is a natural product found in Murraya euchrestifolia and Murraya koenigii with data available.
Biperiden hydrochloride
C21H30ClNO (347.20158000000004)
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
Foliosidine acetonide
Origin: Plant; SubCategory_DNP: Alkaloids derived from anthranilic acid, Quinoline alkaloids, Foliosidine alkaloids
R-4-benzyl-3-((R)-3-hydroxy-2,2-dimethyloctanoyl)oxazolidin-2-one
C20H29NO4 (347.20964740000005)
S-4-benzyl-3-((S)-3-hydroxy-2,2-dimethyloctanoyl)oxazolidin-2-one
C20H29NO4 (347.20964740000005)
Ala Gly Asn Ser
Ala Gly Ser Asn
Ala Asn Gly Ser
Ala Asn Ser Gly
Ala Ser Gly Asn
Ala Ser Asn Gly
Gly Ala Asn Ser
Gly Ala Ser Asn
Gly Gly Lys Ser
Gly Gly Asn Thr
Gly Gly Gln Ser
Gly Gly Ser Lys
Gly Gly Ser Gln
Gly Gly Thr Asn
Gly Lys Gly Ser
Gly Lys Ser Gly
Gly Asn Ala Ser
Gly Asn Gly Thr
Gly Asn Ser Ala
Gly Asn Thr Gly
Gly Gln Gly Ser
Gly Gln Ser Gly
Gly Ser Ala Asn
Gly Ser Gly Lys
Gly Ser Gly Gln
Gly Ser Lys Gly
Gly Ser Asn Ala
Gly Ser Gln Gly
Gly Thr Gly Asn
Gly Thr Asn Gly
Lys Gly Gly Ser
Lys Gly Ser Gly
Lys Ser Gly Gly
Asn Ala Gly Ser
Asn Ala Ser Gly
Asn Gly Ala Ser
Asn Gly Gly Thr
Asn Gly Ser Ala
Asn Gly Thr Gly
Asn Ser Ala Gly
Asn Ser Gly Ala
Asn Thr Gly Gly
Gln Gly Gly Ser
Gln Gly Ser Gly
Gln Ser Gly Gly
Ser Ala Gly Asn
Ser Ala Asn Gly
Ser Gly Ala Asn
Ser Gly Gly Lys
Ser Gly Gly Gln
Ser Gly Lys Gly
Ser Gly Asn Ala
Ser Gly Gln Gly
Ser Lys Gly Gly
Ser Asn Ala Gly
Ser Asn Gly Ala
Ser Gln Gly Gly
Thr Gly Gly Asn
Thr Gly Asn Gly
Thr Asn Gly Gly
GW 9508
C22H21NO3 (347.15213560000007)
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities[1][2][3][4].
S-4-benzyl-3-((S)-3-hydroxy-2,2-dimethyloctanoyl)oxazolidin-2-one
C20H29NO4 (347.20964740000005)
Murrayazolinol
(R)-Mahanine
[5-(4-Methylphenyl)-1,2-oxazol-4-yl](4-phenyl-1-piperazinyl)metha none
Benzpiperylone
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
(3S,4R)-1-(TERT-BUTOXYCARBONYL)-4-(4-TERT-BUTYLPHENYL)PYRROLIDINE-3-CARBOXYLIC ACID
C20H29NO4 (347.20964740000005)
ethyl 2-[1-benzyl-4-(2-ethoxy-2-oxoethyl)piperidin-4-yl]acetate
C20H29NO4 (347.20964740000005)
1-TERT-BUTYL 3-ETHYL 3-BENZYLPIPERIDINE-1,3-DICARBOXYLATE
C20H29NO4 (347.20964740000005)
Methyl 4-((5,6-dimethoxy-1-oxo-2,3-dihydro-1H-inden-2-yl)methyl)piperidine-1-carboxylate
3-Pyridinemethanol, 5-ethyl-4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-
Urea, N-cyclopropyl-N-[(1,2-dihydro-6-methyl-2-oxo-3-quinolinyl)methyl]-N-phenyl- (9CI)
(E)-Methyl 3-(2-((tert-butyldimethylsilyloxy)methyl)furo[3,2-b]pyridin-6-yl)acrylate
3-Pyridinemethanol, 5-ethyl-4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-, (aS,4S)- (9CI)
Adiphenine Hydrochloride
C20H26ClNO2 (347.16519660000006)
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Adiphenine hydrochloride is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC50s of 1.9, 1.8, 3.7, and 6.3 μM for α1, α3β4, α4β2, and α4β4, respectively. Adiphenine hydrochloride has anticonvulsant effects[1][2][3].
3-Pyridinemethanol, 5-ethyl-4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-, (aR,4R)- (9CI)
Methanone, [4-(5-chloro-2-methylphenyl)-1-piperazinyl](3-ethyl-5-methyl-4-isoxazolyl)
C18H22ClN3O2 (347.14004620000003)
Methanone, [4-(3-chlorophenyl)-1-piperazinyl][3-methyl-5-(1-methylethyl)-4-isoxazolyl]
C18H22ClN3O2 (347.14004620000003)
(R)-(+)-N,N-DIMETHYL-1-(1-NAPHTHYL)ETHYLAMINE
C22H21NO3 (347.15213560000007)
Fedrilate
C20H29NO4 (347.20964740000005)
R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent
ETHYL N-BOC-4-BENZYLPIPERIDINE-4-CARBOXYLATE
C20H29NO4 (347.20964740000005)
1-(tert-butoxycarbonyl)spiro[chroMan-4,4-piperidine]-2-carboxylic acid
(2R,4S)-ethyl 5-([1,1-biphenyl]-4-yl)-4-amino-2-methylpentanoate hydrochloride
C20H26ClNO2 (347.16519660000006)
(3R)-3-Piperidinecarboxylic acid, 3-(phenylmethyl)-, 1,2,2-trimethylhydrazide, hydrochloride (1:2)
N-[(2S)-3-Amino-2-hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]acetamide hydrochloride (1:1)
C15H23ClFN3O3 (347.14118900000005)
4-(3-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENOXY)PROPYL)MORPHOLINE
4-(3-(3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propyl)Morpholine
DIETHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(4-F&
C19H22FNO4 (347.15327840000003)
3-Pyridinemethanol, 5-ethyl-4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-, (aR,4R)-rel- (9CI)
3-Pyridinemethanol, 5-ethyl-4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-, (aR,4S)-rel- (9CI)
6-nitro-2-[(4-phenylpiperidin-1-yl)methyl]quinoline
1-TERT-BUTYL 3-METHYL 3-BENZYL-4-OXOPIPERIDINE-1,3-DICARBOXYLATE
4-Cyanophenyl trans-4-(4-propylcyclohexyl)benzoate
N4-ethyl-6-[2-(4-methylphenoxy)ethylthio]-N2-propan-2-yl-1,3,5-triazine-2,4-diamine
4-Methoxy-1-methyl-8-[(2,2,5,5-tetramethyl-1,3-dioxolan-4-yl)methoxy]quinolin-2-one
3-[(4-ethylphenoxy)methyl]-4-(6-methylheptan-2-yl)-1H-1,2,4-triazole-5-thione
C19H29N3OS (347.20312240000004)
N-cyclopropyl-2,6-dimethyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
2-(Cyclohexylmethylamino)-4-(phenylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile
N-(Cyclopropylmethyl)-2-Methyl-5-(5-Methyl-1,3,4-Oxadiazol-2-Yl)biphenyl-4-Carboxamide
(1E,2Z)-3-hydroxy-5,9,17-trioxo-4,5:9,10-disecoandrosta-1(10),2-dien-4-oate
(1R,2R,5R,8R,9S,10R,11R,12R,13S)-12,13-dihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylate
(1R,2R,5S,8S,9S,10R,11R,12S)-5,12-dihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylate
(1R,2R,5S,8S,9S,10R,11S,13R)-5,13-dihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylate
(4R)-4,5-dihydroxy-4,6-bis(3-methylbut-2-enyl)-2-(2-methylpropanoyl)-3-oxocyclohexa-1,5-dien-1-olate
C20H27O5- (347.18583920000003)
(1R,2S,3S,4R,6S,8R,9R,12R)-4-formyl-6-hydroxy-8-(hydroxymethyl)-4-methyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2-carboxylate
C20H27O5- (347.18583920000003)
(3E)-3-(1-hydroxy-2,4-dimethylhexylidene)-5-[hydroxy-(4-hydroxyphenyl)methyl]pyrrolidine-2,4-dione
Leu-Thr-Asp
A tripeptide composed of L-leucine, L-threonine and L-aspartic acid joined in sequence by peptide linkages.
6-(1,3-benzodioxol-5-yl)-N-(cyclopentylmethyl)-4-quinazolinamine
2-hydroxy-2,2-bis(4-methylphenyl)-N-(2-pyridinyl)acetohydrazide
Glu-Ile-Ser
A tripeptide composed of L-glutamic acid, L-isoleucine and L-serine joined by peptide linkages.
N-[(3,5-dimethoxyphenyl)methyl]-1-(2,3,4-trimethoxyphenyl)methanamine
1-[3-(Bicyclo[2.2.1]hept-5-en-2-yl)-3-hydroxy-3-phenylpropyl]piperidine hydrochloride
C21H30ClNO (347.20158000000004)
18-oxoresolvin E1(1-)
C20H27O5- (347.18583920000003)
An icosanoid anion resulting from the removal of a proton from the carboxy group of 18-oxoresolvin E1; major species at pH 7.3.
1-(3-Methoxyphenyl)-3-[5-(2-methyl-1-piperidinyl)-1,3,4-thiadiazol-2-yl]urea
C16H21N5O2S (347.14158860000003)
2-(2,5-dioxo-4,4-dipropyl-1-imidazolidinyl)-N-(3-methoxyphenyl)acetamide
1-[2-(Dimethylamino)ethyl]-3-(2,4-dimethylphenyl)-1-(thiophen-2-ylmethyl)thiourea
2-[(2,2-dimethyl-4-oxo-3,4-dihydro-2H-1-benzopyran-6-yl)oxy]-N-heptylacetamide
C20H29NO4 (347.20964740000005)
(R)-((4S,4aR,5S,8aR)-3,4a,5-trimethyl-9-oxo-4,4a,5,6,7,8,8a,9-octahydronaphtho[2,3-b]furan-4-yl) 2-amino-2-methylbutanoate
C20H29NO4 (347.20964740000005)
A natural product found in Pittocaulon velatum.
3-(1,3-Dihydrobenzimidazol-2-ylidene)-1-pentylquinoline-2,4-dione
7-(diethylamino)-4-(1-methyl-1H-benzimidazol-2-yl)-2H-chromen-2-one
3-ethoxy-N-[[4-[(4-fluorophenyl)methoxy]-3-methoxyphenyl]methyl]-1-propanamine
C20H26FNO3 (347.18966180000007)
5-dioxooctahydro-1H-inden-4-yl]-6-oxoocta-2,4-dienoate
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
(2R,3S,4S)-1-[cyclobutyl(oxo)methyl]-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile
1-[(3aS,4S,9bS)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
1-[(3aR,4R,9bR)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
1-[(3aR,4S,9bR)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
(5S,6Z,8E,10E,14Z)-5-hydroxy-12,20-dioxoicosa-6,8,10,14-tetraenoate
C20H27O5- (347.18583920000003)
(3R,10R)-10-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyundecanoate
(3R)-11-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyundecanoate
Butyl N-trifluoroacetyl 2-N-methylaminoethyl phosphonate
Dibutyl 1-(N-trifuoroacetylamino)propylphosphonate
4-(3-Acetyloxy-2-butanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C16H29NO7 (347.19439239999997)
4-[2,3-Di(propanoyloxy)propoxy]-2-(trimethylazaniumyl)butanoate
C16H29NO7 (347.19439239999997)
methyl {2-[(1R)-1-(3,4-dimethoxyphenyl)-4-oxocyclohex-2-en-1-yl]ethyl}methylcarbamate
Eliprodil
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents Eliprodil(SL-820715) is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM). IC50 value: Target: NR2B-NMDA antagonist Human N-type Ca2+ channel currents were inhibited by ifenprodil and eliprodil with IC50 values of 50 microM and 10 microM respectively whereas P-type Ca2+ channel currents were inhibited reversibly by ifenprodil and eliprodil with approximate IC50 values of 60 microM and 9 microM respectively. eliprodil (1 microm) produced a moderate reverse rate-dependent prolongation of the action potential duration (7.4+/-1.5, 8.9+/-2.1 and 9.9+/-1.8\% at cycle lengths of 300, 1000 and 5000 ms, respectively; n=9).
FPL64176
C22H21NO3 (347.15213560000007)
D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents > D002120 - Calcium Channel Agonists D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
GP531
C16H21N5O4 (347.15934660000005)
GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.
3-(acetyloxy)-1-{8-methyl-2-oxa-6-azatricyclo[5.3.0.0¹,³]deca-6,8-dien-10-ylidene}butan-2-yl 2-methylpropanoate
6-(6-hydroxy-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)-4-[(2-hydroxyethyl)amino]-2-oxopyran-3-carbaldehyde
1-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-2-hydroxy-9h-carbazole-3-carbaldehyde
(5s,9bs,11r,12s)-7,8,11-trimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinoline-5,12-diol
(2z,5r,7r,8s,9r)-15,16-dimethoxy-10-methyl-18-oxa-10-azatetracyclo[7.7.1.1²,⁸.0¹³,¹⁷]octadeca-1(16),2,13(17),14-tetraene-5,7-diol
n-[(3as,4s,5s,11as)-6-formyl-4-hydroxy-10-methyl-3-methylidene-2-oxo-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-5-yl]-2-methylpropanimidic acid
n-{6-formyl-4-hydroxy-10-methyl-3-methylidene-2-oxo-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-5-yl}-2-methylpropanimidic acid
n-[2,4-dihydroxy-5-(3-methoxy-3-oxopropyl)phenyl]-7-methylocta-2,4-dienimidic acid
3-(acetyloxy)-1-[(10z)-8-methyl-2-oxa-6-azatricyclo[5.3.0.0¹,³]deca-6,8-dien-10-ylidene]butan-2-yl 2-methylpropanoate
3-methoxy-4-methyl-5-[(1s,9r,10r,11r,12s,13z)-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-ylidene]furan-2-one
6-(5-hydroxy-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)-4-[(2-hydroxyethyl)amino]-2-oxopyran-3-carbaldehyde
(2s)-n-[(2s)-5-carbamimidamido-1-oxopentan-2-yl]-2-[(1-hydroxyethylidene)amino]-3-phenylpropanimidic acid
1-hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6h,7h-pyrrolo[1,2-a]pyrazin-4-one
4,6,8-trimethoxy-3-[(2s)-2-methoxy-3-methylbut-3-en-1-yl]-1-methylquinolin-2-one
4,5,6-trimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraen-8-ol
(2r,3s)-3-(acetyloxy)-1-[(1r,3s,10z)-8-methyl-2-oxa-6-azatricyclo[5.3.0.0¹,³]deca-6,8-dien-10-ylidene]butan-2-yl 2-methylpropanoate
acanthamolide
{"Ingredient_id": "HBIN014338","Ingredient_name": "acanthamolide","Alias": "NA","Ingredient_formula": "C19H25NO5","Ingredient_Smile": "CC1=CC2C(C(C(C(=CCC1)C=O)NC(=O)C(C)C)O)C(=C)C(=O)O2","Ingredient_weight": "347.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "76","TCMSP_id": "NA","TCM_ID_id": "7248;21448","PubChem_id": "118855998","DrugBank_id": "NA"}
4,6-dihydroxy-12-methoxy-7-methyl-4-(sec-butyl)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
C17H21N3O5 (347.14811360000004)
(3r)-3,5-dimethyl-3-(4-methylpent-3-en-1-yl)-11h-pyrano[3,2-a]carbazol-9-ol
(1s,8r,10r,17r)-4,5,6-trimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraen-8-ol
13,14-dimethyl-3,13,17-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15,17,19-heptaen-13-ium-19-carboxylate
6-[(1r,2s,4ar,5r,8ar)-5-hydroxy-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-4-[(2-hydroxyethyl)amino]-2-oxopyran-3-carbaldehyde
(4e,6e)-7-{[1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]-c-hydroxycarbonimidoyl}-3,5-dimethylhepta-4,6-dienoic acid
n-[(3ar,4s,5s,11ar)-6-formyl-4-hydroxy-10-methyl-3-methylidene-2-oxo-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-5-yl]-2-methylpropanimidic acid
1-({6,10-dimethyl-2-oxo-3h,3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-3-yl}methyl)pyrrolidine-2-carboxylic acid
C20H29NO4 (347.20964740000005)
(1r,9r,12s,13s)-4,11-dimethoxy-17-methyl-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,10-tetraene-3,12,13-triol
4-methoxy-3-methyl-5-[(13e)-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-ylidene]furan-2-one
5-{3,5-dimethyl-11h-pyrano[3,2-a]carbazol-3-yl}-2-methylpent-1-en-3-ol
6-(6-hydroxy-1-methyl-2,3,5,6,7,7a-hexahydroindol-7-yl)-2,3,4-trimethoxybenzaldehyde
(3z)-1-hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6h,7h-pyrrolo[1,2-a]pyrazin-4-one
(2s)-1-{[(3as)-6,10-dimethyl-2-oxo-3h,3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-3-yl]methyl}pyrrolidine-2-carboxylic acid
C20H29NO4 (347.20964740000005)
(1s,16r,19s)-13,16-dimethyl-19-(prop-1-en-2-yl)-15-oxa-4-azapentacyclo[14.3.1.0²,¹⁴.0³,¹¹.0⁵,¹⁰]icosa-2(14),3(11),5(10),6,8,12-hexaen-7-ol
6-[(6r,7s,7as)-6-hydroxy-1-methyl-2,3,5,6,7,7a-hexahydroindol-7-yl]-2,3,4-trimethoxybenzaldehyde
(23r)-13-methoxy-5,7-dioxa-19-azahexacyclo[15.7.0.0²,¹⁰.0⁴,⁸.0¹¹,¹⁶.0¹⁹,²³]tetracosa-1(17),2(10),3,8,11(16),12,14-heptaene
C22H21NO3 (347.15213560000007)
3-methyl-3-(4-methylpent-3-en-1-yl)-2h,11h,11bh-pyrano[2,3-a]carbazole-5-carbaldehyde
(2s)-2-{[(2s,3r)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-1,3-dihydroxybutylidene]amino}butanedioic acid
(2s)-2,7-dimethyl-2-(4-methylpent-3-en-1-yl)-10h-pyrano[2,3-b]carbazol-8-ol
4,6,8-trimethoxy-3-(2-methoxy-3-methylbut-3-en-1-yl)-1-methylquinolin-2-one
(14s,17r,19r)-3,13,13,17-tetramethyl-21-oxa-12-azahexacyclo[10.7.1.1²,¹⁷.0⁵,²⁰.0⁶,¹¹.0¹⁴,¹⁹]henicosa-1,3,5(20),6(11),7,9-hexaen-9-ol
n-{5-acetyl-9-butyl-9-hydroxy-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-6,8(12)-dien-6-yl}ethanimidic acid
C19H29N3O3 (347.22088040000006)
4-methoxy-3-methyl-5-[(1r,9s,10r,11r,12s,13z)-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-ylidene]furan-2-one
(1s,10s,12r,16r)-16-hydroxy-4,5-dimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5-trien-12-yl acetate
4-{[(1r,2r,4as,5r,8ar)-2-ethyl-5-hydroxy-1,6-dimethyl-4-oxo-2,3,4a,5,8,8a-hexahydronaphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2h-pyrrol-3-one
(4r,7r)-4,6-dihydroxy-12-methoxy-7-methyl-4-(sec-butyl)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
C17H21N3O5 (347.14811360000004)
(14r,17s,19r)-3,13,13,17-tetramethyl-21-oxa-12-azahexacyclo[10.7.1.1²,¹⁷.0⁵,²⁰.0⁶,¹¹.0¹⁴,¹⁹]henicosa-1,3,5(20),6(11),7,9-hexaen-9-ol
4-methoxy-3-methyl-5-[(1r,9r,11r,12s,13z)-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-ylidene]furan-2-one
13-methoxy-5,7-dioxa-19-azahexacyclo[15.7.0.0²,¹⁰.0⁴,⁸.0¹¹,¹⁶.0¹⁹,²³]tetracosa-1(17),2(10),3,8,11(16),12,14-heptaene
C22H21NO3 (347.15213560000007)
(2s)-1-{[(3r,3as,11as)-6,10-dimethyl-2-oxo-3h,3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-3-yl]methyl}pyrrolidine-2-carboxylic acid
C20H29NO4 (347.20964740000005)
n-[(1s,4s,9r,10s)-5-acetyl-9-butyl-9-hydroxy-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-6,8(12)-dien-6-yl]ethanimidic acid
C19H29N3O3 (347.22088040000006)
methyl (1s,3s,11r,13r,14e)-3-methoxy-14-(2-methoxy-2-oxoethylidene)-9-azatetracyclo[7.5.0.0¹,⁶.0¹¹,¹³]tetradec-5-ene-13-carboxylate
(1s,13s,16s,18r)-13,18-dimethoxy-15-methyl-5,7,12-trioxa-15-azapentacyclo[11.7.0.0¹,¹⁶.0²,¹⁰.0⁴,⁸]icosa-2,4(8),9-triene
15,16-dimethoxy-10-methyl-18-oxa-10-azatetracyclo[7.7.1.1²,⁸.0¹³,¹⁷]octadeca-1(16),2,13(17),14-tetraene-5,7-diol
n-[(3as,4s,5s,11ar)-6-formyl-4-hydroxy-10-methyl-3-methylidene-2-oxo-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-5-yl]-2-methylpropanimidic acid
(1r,3s,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl (1s)-1-hydroxy-3-(3-methylbut-2-en-1-yl)-4-oxocyclohex-2-ene-1-carboxylate
C20H29NO4 (347.20964740000005)
(1s,13z)-12,12-dimethyl-10,15,21-triazapentacyclo[13.7.0.0³,¹¹.0⁴,⁹.0¹⁷,²¹]docosa-3(11),4,6,8,13,17-hexaene-16,22-dione
13,18-dimethoxy-15-methyl-5,7,12-trioxa-15-azapentacyclo[11.7.0.0¹,¹⁶.0²,¹⁰.0⁴,⁸]icosa-2,4(8),9-triene
7-{[1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]-c-hydroxycarbonimidoyl}-3,5-dimethylhepta-4,6-dienoic acid
13,16-dimethyl-19-(prop-1-en-2-yl)-15-oxa-4-azapentacyclo[14.3.1.0²,¹⁴.0³,¹¹.0⁵,¹⁰]icosa-2(14),3(11),5(10),6,8,12-hexaen-7-ol
methyl (1r,3s,11r,13r,14e)-3-methoxy-14-(2-methoxy-2-oxoethylidene)-9-azatetracyclo[7.5.0.0¹,⁶.0¹¹,¹³]tetradec-5-ene-13-carboxylate
7,8,11-trimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinoline-5,12-diol
(1s,10r,12r)-16-hydroxy-4,5-dimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5-trien-12-yl acetate
4-benzyl-5-hydroxy-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}pyrrol-2-one
C22H21NO3 (347.15213560000007)
4-methoxy-3-methyl-5-{12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-ylidene}furan-2-one
(3r)-5-[(3r)-3,5-dimethyl-11h-pyrano[3,2-a]carbazol-3-yl]-2-methylpent-1-en-3-ol
(3s,11br)-3-methyl-3-(4-methylpent-3-en-1-yl)-2h,11h,11bh-pyrano[2,3-a]carbazole-5-carbaldehyde
(2r)-2,7-dimethyl-2-(4-methylpent-3-en-1-yl)-10h-pyrano[2,3-b]carbazol-8-ol
(1r,5s)-6-(acetyloxy)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate
2,7-dimethyl-2-(4-methylpent-3-en-1-yl)-10h-pyrano[2,3-b]carbazol-8-ol
6-[(6s,7s,7as)-6-hydroxy-1-methyl-2,3,5,6,7,7a-hexahydroindol-7-yl]-2,3,4-trimethoxybenzaldehyde
1-(3,7-dimethylocta-2,6-dien-1-yl)-2-hydroxy-9h-carbazole-3-carbaldehyde
(1r,16r,19s)-13,16-dimethyl-19-(prop-1-en-2-yl)-15-oxa-4-azapentacyclo[14.3.1.0²,¹⁴.0³,¹¹.0⁵,¹⁰]icosa-2(14),3(11),5(10),6,8,12-hexaen-7-ol
5-(4-methoxy-2-methylnaphthalen-1-yl)-3-methyl-1,2-dihydroisoquinoline-6,8-diol
C22H21NO3 (347.15213560000007)